9VC Stock Overview
A clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Atai Life Sciences N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.15 |
| 52 Week High | US$2.47 |
| 52 Week Low | US$0.93 |
| Beta | 1.13 |
| 1 Month Change | -22.43% |
| 3 Month Change | 6.00% |
| 1 Year Change | -9.93% |
| 3 Year Change | -82.87% |
| 5 Year Change | n/a |
| Change since IPO | -89.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9VC | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -12.3% | -2.5% | -2.6% |
| 1Y | -9.9% | -15.6% | 6.9% |
Return vs Industry: 9VC exceeded the German Pharmaceuticals industry which returned -15.6% over the past year.
Return vs Market: 9VC underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| 9VC volatility | |
|---|---|
| 9VC Average Weekly Movement | 13.9% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9VC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9VC's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 83 | Srini Rao | www.atai.life |
Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology.
Atai Life Sciences N.V. Fundamentals Summary
| 9VC fundamental statistics | |
|---|---|
| Market cap | €191.38m |
| Earnings (TTM) | -€123.25m |
| Revenue (TTM) | €317.23k |
603.3x
P/S Ratio-1.6x
P/E RatioIs 9VC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9VC income statement (TTM) | |
|---|---|
| Revenue | US$331.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$331.00k |
| Other Expenses | US$128.93m |
| Earnings | -US$128.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.77 |
| Gross Margin | 100.00% |
| Net Profit Margin | -38,852.87% |
| Debt/Equity Ratio | 17.2% |
How did 9VC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 04:18 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Atai Life Sciences N.V. is covered by 14 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Sumant Satchidanand Kulkarni | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |